Mostrar el registro sencillo del ítem
dc.contributor.author | Pérez-García, Felipe | |
dc.contributor.author | Bailén, Rebeca | |
dc.contributor.author | Torres-Macho, Juan | |
dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Jiménez, Eva | |
dc.contributor.author | Pérez-Butragueño, Mario | |
dc.contributor.author | Cuadros-González, Juan | |
dc.contributor.author | Cadiñanos, Julen | |
dc.contributor.author | García-García, Irene | |
dc.contributor.author | Ryan, Pablo | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2022-05-03T10:41:41Z | |
dc.date.available | 2022-05-03T10:41:41Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Front Med (Lausanne). 2021;8:736028. | es_ES |
dc.identifier.issn | 2296-858X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14238 | |
dc.description.abstract | Background: Endothelial Activation and Stress Index (EASIX) predict death in patients undergoing allogeneic hematopoietic stem cell transplantation who develop endothelial complications. Because coronavirus disease 2019 (COVID-19) patients also have coagulopathy and endotheliitis, we aimed to assess whether EASIX predicts death within 28 days in hospitalized COVID-19 patients. Methods: We performed a retrospective study on COVID-19 patients from two different cohorts [derivation (n = 1,200 patients) and validation (n = 1,830 patients)]. The endpoint was death within 28 days. The main factors were EASIX [(lactate dehydrogenase * creatinine)/thrombocytes] and aEASIX-COVID (EASIX * age), which were log2-transformed for analysis. Results: Log2-EASIX and log2-aEASIX-COVID were independently associated with an increased risk of death in both cohorts (p < 0.001). Log2-aEASIX-COVID showed a good predictive performance for 28-day mortality both in the derivation cohort (area under the receiver-operating characteristic = 0.827) and in the validation cohort (area under the receiver-operating characteristic = 0.820), with better predictive performance than log2-EASIX (p < 0.001). For log2 aEASIX-COVID, patients with low/moderate risk (<6) had a 28-day mortality probability of 5.3% [95% confidence interval (95% CI) = 4-6.5%], high (6-7) of 17.2% (95% CI = 14.7-19.6%), and very high (>7) of 47.6% (95% CI = 44.2-50.9%). The cutoff of log2 aEASIX-COVID = 6 showed a positive predictive value of 31.7% and negative predictive value of 94.7%, and log2 aEASIX-COVID = 7 showed a positive predictive value of 47.6% and negative predictive value of 89.8%. Conclusion: Both EASIX and aEASIX-COVID were associated with death within 28 days in hospitalized COVID-19 patients. However, aEASIX-COVID had significantly better predictive performance than EASIX, particularly for discarding death. Thus, aEASIX-COVID could be a reliable predictor of death that could help to manage COVID-19 patients. | es_ES |
dc.description.sponsorship | This study was supported by grants from Instituto de Salud Carlos III [grant number COV20/1144 [MPY224/20) to AF-R/MÁJ-S]. MÁJ-S and AF-R are supported by Instituto de Salud Carlos III (grant numbers CP17CIII/00007 and CP14CIII/00010, respectively). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | Blood coagulation disorders | es_ES |
dc.subject | Clinical prediction rule | es_ES |
dc.subject | Endothelium | es_ES |
dc.subject | Mortality | es_ES |
dc.title | Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019 | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 34568391 | es_ES |
dc.format.volume | 8 | es_ES |
dc.format.page | 736028 | es_ES |
dc.identifier.doi | 10.3389/fmed.2021.736028 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fmed.2021.736028 | es_ES |
dc.identifier.journal | Frontiers in Medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20/1144 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/MPY224/20 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP17CIII/00007 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP14CIII/00010 | es_ES |